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Abstract
Background Amino acidopathies are a class of inborn errors
of metabolism (IEM) that can be diagnosed by analysis of
amino acids (AA) in plasma. Current strategies for AA anal-
ysis include cation exchange HPLC with post-column ninhy-
drin derivatization, GC-MS, and LC-MS/MS-related
methods. Major drawbacks of the current methods are time-
consuming procedures, derivative problems, problems with
retention, and MS-sensitivity. The use of hydrophilic interac-
tion liquid chromatography (HILIC) columns is an ideal sep-
aration mode for hydrophilic compounds like AA. Here we
report a HILIC-method for analysis of 36 underivatized AA in
plasma to detect defects in AAmetabolism that overcomes the
major drawbacks of other methods.
Methods A rapid, sensitive, and specific method was devel-
oped for the analysis of AA in plasma without derivatization
using HILIC coupled with tandem mass-spectrometry (Xevo
TQ, Waters).
Results Excellent separation of 36 AA (24 quantitative/12
qualitative) in plasma was achieved on an Acquity BEH
Amide column (2.1×100 mm, 1.7 μm) in a single MS run of
18 min. Plasma of patients with a known IEM in AA metab-
olism was analyzed and all patients were correctly identified.
Conclusion The reported method analyzes 36 AA in plasma
within 18 min and provides baseline separation of isomeric
AA such as leucine and isoleucine. No separation was obtain-
ed for isoleucine and allo-isoleucine. The method is applicable
to study defects in AA metabolism in plasma.
Introduction
Amino acids (AA) are important metabolites for the human
body. The metabolites are building blocks for peptides and
proteins, can serve as sources of energy, are precursors for
different metabolites such as neurotransmitters or can act as
neurotransmitters themselves. Disturbances in AA concentra-
tions are not only related to inborn errors of metabolism
(IEM), but AA can also serve as sensitive markers for nutri-
tional status. Besides, AA reflects the function of various or-
gans (Duran, 2008). To diagnose amino acidopathies and for
follow-up of therapy, AA analysis is commonly performed in
biological specimens like plasma, dried blood spots (DBS),
urine, and cerebrospinal fluid. The most commonly used strat-
egies for AA analysis include cation exchange HPLC with
post-column ninhydrin derivatization, GC-MS, and LC-MS/
MS related methods (with and without derivatization). With
respect to time, HPLC with post-column ninhydrin derivati-
zation is less suitable for the modern laboratory with a require-
ment for a rapid turnaround time. Additionally, it is known
that most of the derivatization methods used for LC-MS have
major drawbacks, such as derivative instability and insuffi-
cient reproducibility of the derivative yield (Dolowy and
Pyka 2014; Halket and Zaikin 2005; Kaspar et al 2009).
With the introduction of ion-pairing agents, the separation of
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AA on a C18-reversed phase column improved. Complex
derivatization procedures were no longer necessary and good
separation of compounds was achieved (Piraud et al 2003;
Piraud et al 2005). Unfortunately, problems with retention
time stability and reduction of the sensitivity of the MS-
detector in negative mode arose limiting the use of ion-
pairing reagents (de Person et al 2008; Piraud et al 2005;
Waterval et al 2009).
It is known that polar compounds such as AA and carbo-
hydrates obtain good retention and separation by hydrophilic
interaction liquid chromatography (HILIC) (Buszewski and
Noga 2012; Greco and Letzel 2013; Kahsay et al 2014).
Separation principle is based on the strong interaction of polar
compounds with the hydrophilic phase. A benefit of HILIC is
the use of an aqueous organic solvent eluent that enhances
ionization. With the introduction of HILIC columns for
UPLC new applications, e.g., for AA analysis became within
reach. AAwere analyzed semi-quantitative in fruit (Guo et al
2013; Zhou et al 2013), in rat brain (leucine) (Santos-Fandila
et al 2014), and a subset of AAwas analyzed in animal tissue
hydrolysate (Krumpochova et al 2015). However, no such
analysis was performed in human plasma using HILIC. The
goal of this study was to develop a rapid, sensitive, and spe-
cific method for analysis and quantification of AA in human
plasma without derivatization using HILIC tandem mass-
spectrometry. The method had to be applicable to diagnose
patients with inborn errors of amino acid metabolism. We
validated this method according to ISO-15189 accreditation
for medical laboratories and compared the results with those












leucine, 4,4,5,5,-D4-lysine:2HCl, methyl-D3-methionine, 5,
5-D2-ornithine:HCl, ring-D5-phenylalanine, 2,3,3,4,4,5,5-D7-
proline, 3-13C-serine, 1,2-13C-taurine, U-13C4, U-D5,
15N-thre-
onine, indole-D5-tryptophan, ring-D4-tyrosine, and 1-
13C-va-
line were purchased from Cambridge Isotope Laboratories
(Massachusetts, USA). D9-pipecolic acid was purchased from
CDN-isotopes (Quebec, Canada). D8-homocystine was pur-
chased from Buchem (Apeldoorn, the Netherlands),
13C4-
15N2-asparagine, alanine, delta-aminolevulinic acid, ar-
ginine, asparagine, aspartic acid, argininosuccinic acid (ASA),
citrulline, histidine, homocitrulline, homocysteïne, hydroxy-
proline, isoleucine, leucine, lysine, methionine, methionine-
sulfoxide, methionine-sulfone, phenylalanine, pipecolic acid,
proline, serine, taurine, threonine, tryptophan, tyrosine, valine,
ammon i um f o rm i a t e , a n d DTT ( ( 2S , 3S ) - 1 , 4 -
bis(sulfanyl)butane-2,3-diol) were purchased from Sigma-
Aldrich (Zwijndrecht, the Netherlands). Glutamic acid, gluta-
mine, glycine, ornithine, sulfosalicylic acid (SSA), hydrochlo-
ric acid (HCl), and formic acid were purchased from VWR
(Amsterdam, the Netherlands). Acetonitrile (ACN) and meth-
anol both UPLC-grade were purchased from Biosolve
(Valkenswaard, the Netherlands).
Subjects
Blood samples were obtained for routine diagnostic purposes
from patients suspected for an IEM and collected by venous
puncture into heparin containing tubes (Greiner Bio-One, the
Netherlands). For preparation of quality controls, blood was
taken from a healthy volunteer. Blood was immediately cen-
trifuged and stored at −20 °C. Blood samples were collected
from (untreated) patients with a known inborn of AA metab-
olism including argininosuccinate lyase (ASL) deficiency
(n = 2), 3-phosphoglycerate dehydrogenase deficiency
(n=4), citrullinemia type I (n=1), hyperphenylalaninemia or
phenylketonuria (n= 47), hyperprolinemia type I (n= 2),
lysinuric protein intolerance (LPI) (n = 8), methionine
adenosyltransferase (MAT) Ia deficiency (n=3), maple syrup
urine disease (MSUD) (n=2), methylenetetrahydrofolate re-
ductase (MTHFR) deficiency (n = 3), non-ketotic
hyperglycinemia (NKH (n=6)), ornithine aminotransferase
(OAT) deficiency (n = 4), ornithine-transcarbamyolase
(OTC) deficiency (n=8), and tyrosinemia type I (n=10). All
IEM diagnoses in the control patients were confirmed by
DNA-mutation analysis (data not shown). The samples ob-
tained from the IEM patients were for routine diagnostics
(clinical waste), analyzed anonymously, and not specifically
collected for validation of this study.
Preparation of calibrators
For the calibrators, a solution of 22 AA standards including
hydroxy-proline (IS-I and ST-I, Table 1) was made, while for
glutamine and asparagine a separate standard solution (IS-II
and ST-II, Table 1) was prepared. The internal standards for
IS-I were dissolved in 0.1 M HCl. Subsequently, to 8300 μL
AA mixture (IS-I), 1700 μL 5 % SSA (final concentration
0.85 %) was added. From this 10 mL solution, 20 μL was
added to plasma. IS-II was prepared by addition of 1600 μL
labeled glutamine and 800 μL labeled asparagine to 7600 μL
milliQ-water. From this 10 mL solution 20 μL was added to
plasma. The final concentrations of the labeled AA (IS-I and
IS-II) are shown in Table 1.
ST-I was prepared in 0.1 M HCl and ST-II was prepared in
milliQ-water.
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Standards IS-II and ST-II are unstable in 0.1 M HCl and
need, therefore, to be prepared separately. After thawing of the
standards, the calibrator mixtures were combined and were
analyzed in a single injection. Calibrators were prepared in
the range of 0, 20, 40, 60, 80, and 100 % of the calibration
curve. The absolute concentrations of the calibrators are
shown as supplementary data (Table 1). MilliQ-water was
used as blank (0 %). All solutions were stored at −80 °C.
Quality controls (QCs)
Three QC’s (QC-low, QC-middle, and QC-high) were pre-
pared for quality control. AA concentrations were analyzed
and the obtained values were in the middle range of the cali-
brators (QC-middle). This QC was subsequently diluted with
physiological salt solution to obtain QC-low. For the prepara-
tion of QC-high AA, calibrator (ST-I and ST-II) was added to
QC-middle. QC-low and QC-high were prepared to obtain
AA concentrations in the range of approximately one-third
and two-third of the calibration curve. The absolute concen-
trations of QC-low, QC-middle and QC-high are shown in the
supplementary data (Table 2).
Sample preparation
Forty μL plasma was mixed with 40 μL internal standard
solution consisting of 20 μL labeled AA mixture (IS-I) and
20 μL labeled glutamine and asparagine (IS-II). After
vortexing the patient sample and the IS-mixture, 280 μL sol-
vent A (10 mM ammoniumformiate (final concentration) in
85 % acetonitrile + 0.15 % formic acid) was added. The sam-
ple was vortexed again, subsequently centrifuged for 5 min at
17,000×g in an Eppendorf centrifuge and all of the superna-
tant was transferred to a 96 wells-plate (Waters, Etten-Leur).
After filtration with a 0.2 μMGHP-filter (VWR, Amsterdam)
the sample was ready for analysis.
For the calibrators, 20 μL AA mixture (ST-I, consisting of
22 AA in 0.1 M HCl) was added to 20 μL (ST-II, dissolved in
milliQ-water) (Table 1). To this 40 μL solution, 20 μL (IS-I)
and 20 μL (IS-II) was added ending up with a total volume of
80 μL. The sample preparation for the standards is similar as
described above.
Plasma samples with high AA concentrations were diluted
until the concentrations of the AAwere within the range of the
calibration curve. A 50 fold dilution range was tested and
Table 1 Final concentrations for the internal standards (IS-I and IS-II, +MRM-transitions) and final concentrations for the calibrators ST-I and ST-II
(IS-I) Amino acid Concentration (μM) MRM-transition (m/z) (ST-I) Amino acid Concentration (μM)
1 2,3,3,3-D4-alanine 400 94.1→ 48.1 1 Alanine 2000
2 guanido-15N2-arginine 150 177.1→ 70.2 2 Arginine 500
3 2,3,3-D3-aspartic acid 150 137.0→ 75.1 3 Aspartic acid 200
4 5-13C, 4,4,5,5-D4-citrulline 750 181.2→ 75.1 4 Citrulline 200
5 2,4,4-D3-glutamic acid 400 151.1→ 87.0 5 Glutamic acid 500
6 1,2-13C2-glycine 600 78.0→ 31.1 6 Glycine 2000
7 U-13C6-histidine 200 162.1→ 115.1 7 Histidine 500
8 U-13C6,U-D10,
15N-isoleucine 100 149.1→ 102.2 8 Isoleucine 500
9 5,5,5-D3-leucine 100 135.1→ 89.0 9 Leucine 1000
10 4,4,5,5,-D4-lysine 150 151.1→ 88.1 10 Lysine 1000
11 methyl-D3-methionine 50 153.0→ 107.1 11 Methionine 200
12 5,5-D2-ornithine 150 135.1→ 72.2 12 Ornithine 500
13 ring-D5-phenylalanine 3000 171.1→ 125.1 13 Phenylalanine 500
14 D9-pipecolic acid 25 139.1→ 93.1 14 Pipecolic acid 40
15 2,3,3,4,4,5,5-D7-proline 300 123.1→ 77.1 15 Proline 1000
16 3-13C-serine 400 107.0→ 60.9 16 Serine 1000
17 1,2-13C-taurine 150 128.0→ 110.0 17 Taurine 500
18 U-13C4,U-D5,
15N-threonine 150 130.0→ 83.1 18 Threonine 1000
19 indole-D5-tryptophan 200 210.1→ 150.2 19 Tryptophan 500
20 ring-D4-tyrosine 100 186.1→ 140.1 20 Tyrosine 500
21 1-13C-valine 200 119.1→ 72.1 21 Valine 1000
22 Hydroxy-proline 100
(IS-II) Amino acid Concentration (μM) MRM-transition (m/z) (ST-II) Amino acid Concentration (μM)
1 2,3,3,4,4-D5-glutamine 3200 152.1→ 88.1 1 Glutamine 2000
2 13C4-
15N2-asparagine 400 139.0→ 77.0 2 Asparagine 400
IS-I and ST-I are prepared in 0.1 M HCl and IS-II and ST-II are prepared in milliQ-water
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acceptable and was set as a maximum. Plasma QC-samples
(QC-low, QC-middle, QC-high) were analyzed within each
series of samples. Argininosuccinic acid (ASA), ASA-anhy-
drides, hydroxy-proline, homocitrulline, homocysteine, ho-
mocysteine-cysteine-disulphide, homocystine, and the methi-
onine oxidation products methionine-sulfoxide and
methionine-sulfone were reported semi-quantitatively, while
cystine, cysteine, and delta-aminolevulinic acid were reported
qualitatively.
For method comparison, plasma samples were analyzed on
the JEOL amino acid analyzer (Nieuw-Vennep, the
Netherlands) (de Sain-van der Velden et al 2012; Duran 2008).
Performance characteristics
Performance characteristics for ISO15189-accreditation for
medical laboratories include accuracy, analytical sensitivity,
analytical specificity, carry-over, clinical sensitivity, detection
limit (LOD), interferences, limit of quantitation (LOQ), line-
arity, matrix effect, method comparison, repeatability, repro-
ducibility, stability, and uncertainty of measurement.
The accuracy was determined by analyzing eight samples
of the ERNDIM AA scheme. The analyzed samples included
five samples from 2014 (AA181, AA182, AA183, AA184,
and AA185) and three samples from 2015 (2015-01, 2015-02,
and 2015-03).
Carry-over was determined by analyzing peak area after
multiple injections. An average AA sample list consists of
35 injections including blanks, calibrators, QCs, and patient
samples. An injection scheme is shown in the Table 3 of the
supplementary data.
LOD and LOQ of each AA was determined based on the
S/N-ratio for each AA in QC-low. LOD was calculated as
three times signal to noise (S/N)-ratio, while LOQ was calcu-
lated as ten times signal to noise (S/N)-ratio. Obtained values
were the mean of three independent experiments (performed
at day 1, 5, and 10).
The matrix effect was estimated in triplicate for QC-low
and QC-high and was determined as the ratio of the IS peak
area after sample preparation and IS peak area in milliQ-water.
In the Waters software tool Targetlynx, peak asymmetry pa-
rameters (measure at height 50 %, asymmetry windows 15%)
were set and data were evaluated. One hundred eight samples
were reprocessed and expected asymmetry values (b/a) were
calculated for every AA. The obtained asymmetry parameters
were incorporated in the AA method for peak shape control.
Additionally, absolute and relative intensities of the IS peak
area were checked in every run in all patient samples.
Repeatability was determined by analysis of ten indepen-
dent QCs (5x QC-low and 5x QC-high), that were analyzed
within one run.
Reproducibility was determined by analysis of 20 indepen-
dent QCs (10x QC-low and 10x QC-high). Each set of QCs
(1x QC-low and 1x QC-high) was analyzed at ten consecutive
days. The uncertainty of measurement was defined as twice
the reproducibility.
Chromatographic separation of AA
The chromatographic separation for plasmawas carried out on
an Acquity UPLC BEHAmide column (2.1×100mm, 1.7 μm
particle size) including a Van Guard™ UPLC BEH Amide
pre-column (2.1×5 mm, 1.7 μm particle size) (Waters,
Milford, USA). The column was maintained at a temperature
of 35 °C and the sample volume injected was 2 μL. Optimal
chromatographic separation was achieved at a flow-rate of
0.4 mL/min using a gradient with solvent A (10 mM
ammoniumformiate in 85 % acetonitrile containing 0.15 %
formic acid) and solvent B (10 mM ammoniumformiate in
milliQ-water containing 0.15 % formic acid pH 3.0) as fol-
lows. Initial conditions were 100 % solvent A. After 6 min a
gradient started for 0.1 min (6.0–6.1 min) and solvent A was
decreased to 94.1 % and solvent B increased to 5.9 %. From
6.1 to 10 min solvent Awas set at 82.4 % and solvent B was
set at 17.6 % and from 10 to 12 min, solvent A was set at
70.6 % and solvent B was set at 29.4 % (Table 4,
supplementary data). Then the column was equilibrated for
6 min in the initial conditions. Total run time was 18 min
including column equilibration. The column was coupled to
the mass spectrometer.
Instruments
A Xevo-TQ MS triple quadrupole mass spectrometer
with an electrospray ionization (ESI) source and an
Acquity UPLC-system (Waters, Manchester, United
Kingdom) were used. MassLynx software (v4.1;
Waters, Manchester, United Kingdom) was used for in-
struments’ control and data acquisition. The mass spec-
trometer operated in ESI-positive mode, capillary volt-
age 1.00 kV, desolvation temperature 550 °C, source
temperature 150 °C, cone gas flow 50 L/h, and
desolvation gas flow was 1000 L/h. Collision energy
and cone voltage were optimized for each AA and the
compounds of interest were analyzed using multi reac-
tion monitoring (MRM). The dwell time was set at au-
tomatically. The MRM-transitions for the AA internal
standards and compounds of interest are shown in
Tables 1 and 2, respectively.
Statistical analysis
Analyse-it (Microsoft, v2.12) was used for method compari-
son using Altman-Bland testing.
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Results
Chromatographic separation of AA
All AAwere baseline separated in less than 13 min including
leucine and isoleucine. Total analytical run time was 18 min.
The retention times of the individual AA are shown in Table 2.
Validation
The performance characteristics of this method are shown in
Table 3. Accuracy ranged from 78.8 % for asparagine to
121.8 % for aspartic acid.
During the validation experiments no relevant carry-over
was noticed. In addition, no influence of interfering com-
pounds such as clobazam, colecalciferol, depakine, diazepam,
esomeprazol, levetiracetam, levocarnitine, macrogol, midazo-
lam, ondansetron syrup, paracetamol, and thiamine or a spe-
cial nutritional formula such as a ketogenic diet was noticed.
The LOD (range 0.0002–0.11 μmol/L) and LOQ (range
0.001–0.36 μmol/L) were calculated and were low enough
to diagnose patients with an IEM of AA metabolism, thereby
fulfilling the criteria of analytical sensitivity.
The matrix effect was studied and was highly variable for
QC-low and QC-high ranging from 16.9 % for valine to
358.6 % for threonine respectively, but did not influence the
LOD or LOQ.
The linearity of the calibration curve of each individ-
ual AA ranged from 20 μmol/L for pipecolic acid to at
least 1000 μmol/L for alanine, glycine, and glutamine.
Linearity was not further tested and for diagnostic pur-
poses samples with AA concentrations above the highest
value of the calibration curve were diluted with physio-
logical salt solution and re-analyzed. The r2 of the cali-
bration curve (Table 3) was the mean r2 of the calibration
curve measured at three independent days (day 1, 5, and
10). Additionally, in Table 5 (supplementary data), the
slope of each individual calibration curve measured at
three independent days (day 1, 5, and 10) is presented.
The repeatability and reproducibility variations for
the quantitative AA were determined by analyzing QC-
samples. The repeatability (n = 5) for the quantitative
AA tested ranged from 0.8 to 6.9 %, while the repro-
ducibility (n= 10) ranged from 3.5 to 16.7 %. For hy-
droxy-proline, with the highest variation in reproducibil-
ity (16.7 %), labeled threonine was used for quantifica-
tion instead of labeled hydroxy-proline. Therefore the
analysis of hydroxy-proline can be considered to be
semi-quantitative only. Reproducibility for all other AA
was less than 10.9 %. The uncertainty of measurement
was, with the exclusion of hydroxy-proline, below
21.6 % for all AA.
Method comparison
As part of the validation procedure, the described method was
compared with cation exchange HPLC with post-column nin-
hydrin derivation. Forty-one samples were analyzed using
JEOL amino acid analyzer and with HILIC UPLC tandem
mass-spectrometry. Six out of 23 AA including hydroxy-
proline (3.7 μM, p < 0.01), serine (8.3 μM, p < 0.0001),
aspartic acid (1.9 μM, p < 0.01), histidine (5.2 μM,
p < 0.0001), lysine (9.0 μM, p < 0.0001), and ornithine
(8.2 μM, p<0.001) were significantly different. The small
bias is of no clinical importance and therefore the differences
were accepted.
Tryptophan is an AA that tends to bind to proteins and is
sensitive to the deproteinization process. For the JEOL AA
analyzer, AA are precipitated exclusively in 100 μL 5 % SSA
and not in a combination of ACN and SSA. The use of SSA in
particular is contra-indicated when quantifying tryptophan
(Duran 2008) and therefore this AA was excluded for the
comparison.
Analysis of patient samples
To test the specificity of the method, plasma samples were
analyzed from (untreated) patients with a known inborn error
of AA metabolism (see Subjects section). In total, 97 plasma
samples were analyzed and in 95 samples the metabolites of
interest were elevated/reduced or identified, resulting in a clin-
ical sensitivity of 97.9 %. In two plasma samples of MSUD-
subjects elevated concentrations branched chain AA were
identified. Since isoleucine and d-allo-isoleucine could not
be separated, the patient samples were suggested to be of
MSUD origin, but could not be definitely identified as
MSUD.
In the plasma of two patients with MTHFR deficiency, the
homocysteine-related metabolites were initially not detected,
since homocysteine was lost during sample clean up. To over-
come this problem, DTT (final concentration of 10.9 mmol/L)
was added before the precipi tat ion step (10 μM
ammoniumformiate in 85% acetonitrile + 0.15% formic acid)
and the samples were reanalyzed. Homocysteine was clearly
present. In our laboratory, we have a method available for
quantifying homocysteine (de Sain-van der Velden et al
2015) and since DTTwas only added to qualify homocysteine
in this method, we decided to leave the reducing agent out of
the sample-precipitation step. Additional experiments showed
that DTT can be safely added to the sample preparation pro-
cedure, without affecting the quantification of the compounds
of interest (data not shown) and thus, quantification of homo-
cysteine can be incorporated as well.
In Fig. 1, the abnormal metabolites in a patient with MAT-
Ia, ASL-deficiency on treatment and citrullinemia type I are
shown. In MAT-Ia deficiency, a high methionine was
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observed. The sulfur-group of methionine can oxidize to form
methionine-sulfoxide and methionine-sulfone (Fig. 1a). For
diagnostic follow-up of the high methionine, the sample was
re-analyzed after the addition of DTT (final concentration of
10.9 mmol/L) and a slightly elevated homocysteine was no-
ticed (data not shown) that was quantified (14.5 μmol/L,
n<12.5 μmol/L) according to the method described in (de
Sain-van der Velden et al 2015). In Fig. 1b, the AA abnormal-
ities of a patient with ASL-deficiency on treatment (citrulline)
was shown. As a consequence of the metabolic block,
argininosuccinic acid (ASA) accumulates and loss of water
results in the formation of ASA-anhydrides. In Fig. 1c, the
AA abnormalities in a patient with citrullinemia type I was
shown. Next to an increased concentration of citrulline, the
presence of homocitrulline was noticed.
In approximately 30 min (including sample preparation) a
total AA profile is generated. One can argue, that this is incor-
rect, since for quantitative purposes a calibration curve needs
to be analyzed as well. Indeed, for every series of AA, we
analyze a calibration curve consisting of six calibrators










1 Tryptophan 2.6 205.1→ 146.0 18 18 indole-D5-tryptophan
2 Phenylalanine 2.6 166.1→ 120.1 20 15 ring-D5-phenylalanine
3 Leucine 2.9 132.1→ 86.1 15 10 5,5,5-D3-leucine
4 Isoleucine 3.1 132.1→ 86.1 15 10 U-13C6,U-D10,
15N-isoleucine
5 Allo-isoleucine 3.1 132.1→ 86.1 15 10 –
6 Methionine 3.5 150.0→ 104.0 16 10 methyl-D3-methionine
7 Homocysteine 3.9 136.0→ 90.0 15 10 D8-homocystine
8 Homocysteine-cysteine disulphide 4.0 255.0→ 134.0 15 10 D8-homocystine
9 Valine 4.2 118.1→ 72.1 18 10 1-13C-valine
10 d-aminolevulinic acid 4.2 132.0→ 86.0 15 15 –
11 Proline 4.3 116.0→ 70.1 20 10 2,3,3,4,4,5,5-D7-proline
12 Tyrosine 4.4 182.1→ 136.1 20 15 ring-D4-tyrosine
13 Pipecolic acid 4.6 130.1→ 84.1 20 15 D9-pipecolic acid
14 Taurine 4.6 126.0→ 108.0 26 11 1,2-13C-taurine
15 Cysteine 4.9 122.0→ 76.0 12 10 –
16 Methionine-sulfone 5.1 182.1→ 56.0 20 18 methyl-D3-methionine
17 Alanine 7.0 90.1→ 44.1 15 8 2,3,3,3-D4-alanine
18 Hydroxy-proline 7.1 132.1→ 68.0 18 12 U-13C4,U-D5,
15N-threonine
19 Threonine 7.7 120.0→ 74.1 15 10 U-13C4,U-D5,
15N-threonine
20 Glycine 7.9 76.0→ 30.1 15 6 1,2-13C2-glycine
21 Methionine-sulfoxide 8.4 166.0→ 74.0 15 14 methyl-D3-methionine
22 Glutamine 8.6 147.1→ 84.1 15 15 2,3,3,4,4-D5-glutamine
23 Serine 8.6 106.0→ 60.0 15 10 3-13C-serine
24 Asparagine 8.7 133.0→ 74.0 16 14 13C4-
15N2-asparagine
25 Homocitrulline 8.8 189.9→ 172.9 12 12 5-13C, 4,4,5,5-D4-citrulline
26 Citrulline 9.0 176.1→ 159.0 15 10 5-13C, 4,4,5,5-D4-citrulline
27 Glutamic acid 9.1 148.0→ 84.0 18 16 2,4,4-D3-glutamic acid
28 Aspartic acid 9.9 134.0→ 74.0 15 15 2,3,3-D3-aspartic acid
29 Histidine 10.3 156.1→ 110.0 15 15 U-13C6-histidine
30 Arginine 10.5 175.1→ 70.1 25 20 guanido-15N2-arginine
31 Lysine 10.8 147.1→ 84.1 20 15 4,4,5,5,-D4-lysine
32 Ornithine 10.9 133.1→ 70.1 15 15 5,5-D2-ornithine
33 Homocystine 10.9 269.0→ 136.0 15 10 D8-homocystine
34 ASA-anhydrides 11.0 273.2→ 70.2 25 25 5-13C, 4,4,5,5-D4-citrulline
35 Cystine 11.9 240.9→ 74.0 20 20 –
36 Argininosuccinic acid (ASA) 12.1 291.2→ 70.2 25 25 5-13C, 4,4,5,5-D4-citrulline
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increasing the analysis time for urgent diagnostics with ap-
proximately 110 min. Therefore, we investigated whether it
was possible to calculate AA in a plasma sample on a calibra-
tion curve that was analyzed earlier. Twenty-one samples in
which AA were analyzed, were reprocessed and calculated
using three different (independent) calibration curves that
were analyzed during the previous week. The data were repro-
ducible except for asparagine. The CV for the other AA was
below 15 % and was lower than the uncertainty of measure-
ment of the analysis. This implies that for urgent diagnostics a
temporary interpretation of the AA results can be given within
30min (including sample preparation and sample processing).
Discussion
Here, we present an accurate and rapid method using HILIC-
chromatography coupled to tandem mass-spectrometry for
analysis of AA and related metabolites in human plasma.
The method was validated according to ISO15189 accredita-
tion for medical laboratories and can be used for diagnosis and
follow-up of patients with an IEM of AA metabolism.
The method is fast, the sample preparation is simple, no
derivatization procedure is needed, and the total runtime (in-
cluding equilibration) is only 18 min. The method is sensitive
(low LOD and LOQ) and reproducible. Currently, more than
6000 AA runs (approximately 1500 analyses/column) have
been performed in our lab and no shift in retention times has
been observed, implying that in contrast to other tandem
mass-spectrometric methods (Piraud et al 2005; Waterval
et al 2009) HILIC-chromatography is stable over time. From
our experience, for assessing column performance, aspartic
acid and tyrosine are the first 2 AA for which the peak shape
worsens, while leucine and iso-leucine are still baseline
resolved.
Recently, Krumpochova et al (Krumpochova et al 2015)
compared different AA analysis procedures and reported that
HILIC showed the least accurate results and the longest

















1 Tryptophan 101.7 0.00 0.0 0.0 0.0–250.0 0.999 2.7 3.5 7.0
2 Phenylalanine 98.0 0.03 0.0 0.0 0.0–250.0 0.998 2.3 3.9 7.8
3 Leucine 100.9 0.08 0.0 0.1 0.1–500.0 0.999 2.4 4.1 8.2
4 Isoleucine 108.2 0.03 0.1 0.3 0.3–250.0 0.998 2.5 5.3 10.6
5 Valine 93.8 0.04 0.1 0.4 0.4–500.0 0.994 6.0 5.9 11.8
6 Methionine 84.0 0.00 0.0 0.0 0.0–100.0 0.998 1.9 4.2 8.4
7 Proline 100.8 0.05 0.0 0.1 0.1–500.0 0.998 2.4 4.9 9.8
8 Tyrosine 100.6 0.12 0.0 0.1 0.1–250.0 0.998 3.8 4.0 8.0
9 Pipecolic acid 98.1 0.03 0.0 0.0 0.0–20.0 0.999 0.8 6.6 13.2
10 Taurine 93.0 0.15 0.0 0.0 0.0–250.0 0.993 2.5 4.7 9.4
11 Alanine 96.7 0.06 0.1 0.3 0.3–
1000.0
0.999 1.9 3.5 7.0
12 Hydroxy-
proline
98.8 0.00 0.0 0.0 0.0–50.0 0.997 3.0 16.7 33.4
13 Threonine 95.3 0.04 0.0 0.0 0.0–500.0 0.998 2.9 6.2 12.4
14 Glycine 97.3 0.03 0.0 0.1 0.1–
1000.0
0.994 3.8 8.0 16.0
15 Glutamine 91.2 0.00 0.1 0.2 0.2–
1000.0
0.996 1.8 5.2 10.4
16 Serine 84.6 0.33 0.0 0.1 0.1–500.0 0.994 4.8 5.4 10.8
17 Asparagine 78.8 0.00 0.0 0.0 0.0–200.0 0.995 3.0 6.2 13.2
18 Citrulline 94.6 0.02 0.0 0.0 0.0–100.0 0.998 4.0 5.3 10.6
19 Glutamic acid 114.2 0.00 0.0 0.1 0.1–250.0 0.998 3.4 4.4 8.8
20 Aspartic acid 121.8 0.74 0.0 0.0 0.0–100.0 0.993 6.9 10.8 21.6
21 Histidine 101.0 0.05 0.0 0.1 0.1–250.0 0.999 2.3 3.5 7.0
22 Arginine 108.6 0.09 0.0 0.1 0.1–250.0 0.998 1.7 4.6 9.2
23 Lysine 102.0 0.00 0.0 0.1 0.1–500.0 0.999 2.2 4.4 8.8
24 Ornithine 98.2 0.03 0.0 0.1 0.1–250.0 0.999 2.9 4.7 9.4
The r2 of the calibration curve was the mean r2 of the calibration curve measured at three independent days (day 1, 5, and 10)
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analysis time (40 min) in comparison with GC-MS and
LC-MS. In the method reported here, total analysis time
was 18 min and nearly a double amount of compounds
are quantified. In contrast to the HILIC method described
by Krumpochova et al (Krumpochova et al 2015) we
used a different column, different mobile additives, and
a lower pH-value for separation of AA. It is well known
that a reduction in particle size could provide higher
sensitivity and selectivity, a better resolution, narrower
peaks, and shorter retention when analyses are
performed on a 1.7 μm particles column instead of a
5 μm particles column. In addition, Guo et al (2013)
showed that ammoniumformiate used as a salt additive
of the mobile phase and a lower pH value of the buffer,
resulted in much better peak shapes for AA analysis.
With these alterations in mind, and since the method is
easy to adapt, we believe that HILIC is favorable to GC-
and LC-MS methods.
In the validation procedure, we tested the specificity of this
method by analyzing AA profiles of patients with a known
IEM of AA metabolism. In plasma specimens of two MSUD-
patients (classical form), in which an increased concentration
of D-allo-isoleucine was initially demonstrated by JEOL ami-
no acid analyzer, D-allo-isoleucine was not identified. As is
known, D-allo-isoleucine can be normal in MSUD (Puckett
et al 2010), but this was not the case in these two patients. D-
allo-isoleucine and isoleucine have an equal molecular weight
and D-allo-isoleucine was not separated from isoleucine.
Therefore, we investigated an alternative approach for diag-
nosing MSUD. The region4database is for NBS samples an-
alyzed from bloodspots (McHugh et al 2011) and data from
this region4database show that the median for leucine is
higher than valine in patients with MSUD. Therefore, we in-
vestigated whether the leucine/valine ratio in plasma could be
used to diagnose patients with MSUD. Leucine/valine-ratio
was calculated in controls (n = 900) and was 0.33–0.98
Citrulline 176.1 > 159
ASA anhydrides 273.2 > 70.2
ASA 291.2 > 70.2 
Methionine 150.0 > 104.0 
Methionine sulfone 182.1 > 56.0 
Methionine sulfoxide 166.1 > 74.0 
Homocitrulline 189.9 >172.9 




Fig. 1 a Amino acid abnormalities observed in a plasma specimen of a
patient with MAT-Ia deficiency, b Amino acid abnormalities in a plasma
specimen of a patient with ASL-deficiency treated with citrulline, ASA:
argininosuccinic acid, c Amino acid abnormalities in a plasma specimen
of a patient with citrullinemia type I
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(range). In plasma samples from two patients with MSUD
(classical form), the leucine/valine-ratios were 1.55 and 4.49
respectively, suggesting that this algorithm might be predic-
tive for classical MSUD. However, more data are needed from
MSUD patients to assess the value of the leucine/valine ratio
as a potential diagnostic indicator for MSUD. After diagnosis,
long-term management comprises a life-long strict and care-
fully adjusted semisynthetic diet and the ratio is therefore of
less value.
Plasma of a patient with citrullinemia type I was analyzed
and apart from the expected abnormal concentrations for cit-
rulline, glutamine, alanine, arginine, and orotic acid an in-
creased concentration (semi-quantitative) of homocitrulline
was observed (Fig. 1c). The presence of homocitrulline is
not only known for citrullinemia type I, but can also be found
in o the r cond i t ions such as hype rammonemia -
hyperornithinemia-homocitrullinuria (HHH) syndrome,
hyperlysinemia (Hommes et al 1983), lysinuric protein intol-
erance (LPI) (Kato et al 1989), and certain artificial formulas
(Metwalli et al 1998). Our patient with citrullinemia type I, did
not get artificial formula feeding.
Besides plasma, this method is also applicable for CSF and
urine (data not shown). For the analysis of AA in CSF, adap-
tations in sample preparation volume and injection volume
were essential. For CSF, validation studies are underway. To
reduce the matrix effect, urine samples were diluted with
milliQ-water, before sample preparation. Other compounds
not analyzed in plasma or CSF (e.g., phospho-ethanolamine
aspartylglucosamine, glycylproline, homoarginine) are cur-
rently investigated, before validation studies are initiated.
Next this method for AA analysis was applied to different
cell-systems (such as HEK293-cells and neuro2A-cells), cell
culture supernatant, and medium. Cells were lysed in 100 %
methanol and 40 μL cell-lysate or cell culture supernatant was
used for AA analysis. Apart from adapting the range of the
calibrators, no adaptation was needed for sample preparation
or analysis of AA, suggesting that the method is robust.
Despite the advantages of the presented method, which is
currently used as the front-line clinical plasma AA method in
our laboratory, this method also has limitations. Currently, we
are unable to separate isoleucine and D-allo-isoleucine.
Several parameters including solvent concentration and pH
were adapted, but did not yield satisfactory results yet (sepa-
ration of isoleucine and D-allo-isoleucine). As a consequence,
monitoring patients with a known diagnosis of MSUD is, for
dietary compliance, thus less appropriate. Since D-allo-
isoleucine is not separated from isoleucine, patients with an
intermittent/variant form of MSUD will be missed. In these
cases and when MSUD is suspected, plasma samples need to
be analyzed with an alternative approach such as an amino
acid analyzer.
Secondly, a limited set of medication and special diets were
tested as interfering compounds for AA analysis. The
medication and special diets examined are frequently used in
the NICU settings. Results from these experiments demon-
strate no interference with the AA analysis presented.
However, we are aware that a limited set of medication is
tested.
In conclusion a method is presented for quantification of
underivatized AA in plasma by HILIC coupled to tandem
mass-spectrometry. The method is fast, is easy to adapt, sen-
sitive and reproducible, and is applicable for diagnosis and
follow-up of patients with defect in amino acid metabolism.
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